Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
Clinical trial NCT04287829 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04287829
- Sponsor
- The Netherlands Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2024-12-05
- Enrollment
- 58
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.